Off-label prescribing in pain medicine practice
FPM has published a new guidance document to inform the professional practice of FPM fellows and trainees.
The ethical and legal framework surrounding off-label prescribing in pain medicine has been a topic of discussion since the establishment of the Faculty of Pain Medicine (FPM). This complex issue arises from the need to balance patient care, professional judgment, and adherence to regulatory and ethical standards.
The faculty resolved to adopt the seven guiding principles for off label prescribing articulated by the Council of Australian Therapeutic Advisory Groups (CATAG) in their 2013 document entitled Rethinking medicines decision-making in Australian Hospitals; Guiding principles for the quality use of off label medicines.
A guidance document has been formulated to articulate the consensus views of the faculty leadership as well as reflect legal and ethical principles to inform the professional practice of FPM fellows and trainees.
For further information, please contact the faculty.
You might also be interested in...
ANZCA has called for the federal government and shadow government to consider and deliver on six priorities and calls for action as part of the 2025 federal election.
New this month: updated GLP-1 Agonist guideline; Propofol supply issues in NZ; Discontinuation of Bridion; RCH sepsis guidelines; webAIRS article in ANZCA Bulletin (Autumn ed.)
Your monthly digest of professional document updates.